Quantum Private Wealth LLC Buys 400 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Quantum Private Wealth LLC increased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 38,661 shares of the biopharmaceutical company’s stock after acquiring an additional 400 shares during the quarter. Intra-Cellular Therapies comprises 1.0% of Quantum Private Wealth LLC’s investment portfolio, making the stock its 16th biggest position. Quantum Private Wealth LLC’s holdings in Intra-Cellular Therapies were worth $2,829,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Headlands Technologies LLC bought a new stake in shares of Intra-Cellular Therapies in the 1st quarter valued at $32,000. Summit Securities Group LLC bought a new position in shares of Intra-Cellular Therapies in the second quarter valued at approximately $56,000. CWM LLC raised its stake in Intra-Cellular Therapies by 83.9% in the second quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 626 shares in the last quarter. EntryPoint Capital LLC increased its stake in shares of Intra-Cellular Therapies by 138.7% in the first quarter. EntryPoint Capital LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 1,259 shares during the period. Finally, Cetera Trust Company N.A boosted its holdings in Intra-Cellular Therapies by 24.8% in the third quarter. Cetera Trust Company N.A now owns 2,520 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 500 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Up 1.2 %

NASDAQ:ITCI opened at $90.51 on Friday. The stock’s 50 day moving average price is $76.42 and its 200 day moving average price is $73.65. The company has a market capitalization of $9.60 billion, a PE ratio of -104.03 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a 52-week low of $52.88 and a 52-week high of $91.68.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.25) earnings per share. As a group, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.62 EPS for the current fiscal year.

Analysts Set New Price Targets

ITCI has been the topic of a number of analyst reports. The Goldman Sachs Group dropped their price target on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Royal Bank of Canada boosted their price objective on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. UBS Group dropped their price target on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Finally, Piper Sandler upgraded Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and increased their target price for the company from $68.00 to $92.00 in a research report on Friday, September 6th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of “Moderate Buy” and a consensus target price of $97.23.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 34,396 shares of Intra-Cellular Therapies stock in a transaction on Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $77,962,764.36. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the sale, the executive vice president now owns 29,700 shares in the company, valued at $2,229,876. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Sharon Mates sold 34,396 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $77,962,764.36. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 175,316 shares of company stock valued at $13,037,345 over the last three months. 2.60% of the stock is currently owned by insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.